{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"KALA BIO, Inc."},"Symbol":{"label":"Symbol","value":"KALA"},"Address":{"label":"Address","value":"100 BEAVER STREET,SUITE 201, WALTHAM, Massachusetts, 02453, United States"},"Phone":{"label":"Phone","value":"+1 781 996-5252"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.kalarx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Mark T. Iwicki","title":"Chairman & Chief Executive Officer"},{"name":"Romulus Kim Brazzell","title":"Chief Medical Officer, Head-Research & Development"},{"name":"Todd Bazemore","title":"President & Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}